Annovis Bio Inc. provided updates for 2024, highlighting progress in clinical trials for neurodegenerative diseases.
From GlobeNewswire: 2025-03-21 17:05:00
Annovis Bio Inc. provided updates and financial results for 2024, highlighting progress in clinical trials for Alzheimer’s and Parkinson’s diseases. The FDA cleared the Company for a pivotal Phase 3 trial in early AD, with promising results from previous studies. Annovis also added new professionals and expanded its patent portfolio. Financially, research and development expenses decreased in the fourth quarter of 2024, with a net loss per common share of $0.43. The Company’s cash and cash equivalents totaled $10.6 million as of December 31, 2024. Annovis remains focused on advancing its innovative therapies for neurodegenerative diseases.
In 2024, Annovis made significant advancements in its clinical programs for Alzheimer’s and Parkinson’s diseases, with positive results from Phase 2/3 trials. The FDA cleared the Company for a pivotal Phase 3 trial for early AD, which began in 2025. Annovis also expanded its team, participated in scientific conferences, and published findings in peer-reviewed journals. Financially, research and development expenses decreased in the fourth quarter of 2024, with a net loss per common share of $0.43. The Company’s cash and cash equivalents totaled $10.6 million as of December 31, 2024, supporting its operations into late 2025. Annovis continues to focus on developing transformative therapies for neurodegenerative diseases.
Read more at GlobeNewswire: Annovis Provides Corporate Updates and Reports Fourth